VERTEX PHARMACEUTICALS
Lobbying client. Federal LDA filings.
- Source id
127178- General description
- Global biotechnology company.
- State
- MA
- Country
- US
- Principal place of business
- US
- Government-entity client
- false
- Effective date
- 2011-01-01
- Total spend (across 1 ingested filings)
- $60,000
Filings (1) — $60,000
| Posted | Type | Year | Lobbying firm | Income |
|---|---|---|---|---|
| 2026-04-19 | Q1 | 2026 | TIBER CREEK GROUP | $60,000 |
Connected on the graph
41 typed relationships in the influence graph — 33 inbound, 8 outbound, grouped by type.
lobbied for (19)
| date | dir | entity | amount | role | source |
|---|---|---|---|---|---|
| — | ← | Jonathon Jones | — | lda_lobbyist_client | |
| — | ← | Daniel Howard Zawitoski | — | lda_lobbyist_client | |
| — | ← | Emily Kirlin | — | lda_lobbyist_client | |
| — | ← | Kate Kalutkiewicz | — | lda_lobbyist_client | |
| — | ← | Matthew O Schumaker | — | lda_lobbyist_client | |
| — | ← | Swarna Vallurupalli | — | lda_lobbyist_client | |
| — | ← | Joshua David Odintz | — | lda_lobbyist_client | |
| — | ← | Kyle Hill | — | lda_lobbyist_client | |
| — | ← | Adam Buckalew | — | lda_lobbyist_client | |
| — | ← | Adam Buckalew | — | lda_lobbyist_client | |
| — | ← | Hazen Clay Marshall | — | lda_lobbyist_client | |
| — | ← | Michael Hayes | — | lda_lobbyist_client | |
| — | ← | Laura Friedel | — | lda_lobbyist_client | |
| — | ← | Veronica Jackson | — | lda_lobbyist_client | |
| — | ← | Hannah Beth Cornwell | — | lda_lobbyist_client | |
| — | ← | Monica Popp | — | lda_lobbyist_client | |
| — | ← | Andrew Joseph Siracuse | — | lda_lobbyist_client | |
| — | ← | E. Brandon Garrett | — | lda_lobbyist_client | |
| — | ← | Mike Mckay | — | lda_lobbyist_client |
lobbies for (11)
| date | dir | entity | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | ← | VERTEX PHARMACEUTICALS INCORPORATED | $1,140,000 | lda_filing | |
| 2026-01-01 | ← | HOLLAND & KNIGHT LLP | $20,000 | lda_filing | |
| 2026-01-01 | ← | MARSHALL & POPP, LLC | $60,000 | lda_filing | |
| 2026-01-01 | ← | SALT POINT STRATEGIES | $10,000 | lda_filing | |
| 2026-01-01 | ← | ALB SOLUTIONS | — | lda_filing | |
| 2026-01-01 | ← | ALB SOLUTIONS | $50,000 | lda_filing | |
| 2026-01-01 | ← | EMPIRE CONSULTING GROUP | $50,000 | lda_filing | |
| 2026-01-01 | ← | ALSTON & BIRD LLP | — | lda_filing | |
| 2025-01-01 | ← | SALT POINT STRATEGIES | — | lda_filing | |
| 2025-01-01 | ← | MARSHALL & POPP, LLC | — | lda_filing | |
| 2025-01-01 | ← | MCLARTY INBOUND LLC | — | lda_filing |
lobbies on bill (8)
| date | dir | entity | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | → | Alternatives to PAIN Act HR 1227 · introduced 2025-02-12 · latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determ… | — | H.R. 1227 | lobbying_bill_mention |
| 2026-01-01 | → | Cameron’s Law HR 1414 · introduced 2025-02-18 · latest action: Referred to the House Committee on Ways and Means. | — | H.R. 1414 | lobbying_bill_mention |
| 2026-01-01 | → | New Era of Preventing End-Stage Kidney Disease Act HR 1518 · introduced 2025-02-24 · latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determ… | — | H.R. 1518 | lobbying_bill_mention |
| 2026-01-01 | → | HELP Copays Act HR 6423 · introduced 2025-12-04 · latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determ… | — | H.R. 6423 | lobbying_bill_mention |
| 2026-01-01 | → | Alternatives to PAIN Act S 475 · introduced 2025-02-06 · latest action: Read twice and referred to the Committee on Finance. | — | S. 475 | lobbying_bill_mention |
| 2026-01-01 | → | Alternatives to PAIN Act HR 1227 · introduced 2025-02-12 · latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determ… | — | H.R. 1227 | lobbying_bill_mention |
| 2026-01-01 | → | Alternatives to PAIN Act S 475 · introduced 2025-02-06 · latest action: Read twice and referred to the Committee on Finance. | — | S.475 | lobbying_bill_mention |
| 2026-01-01 | → | Alternatives to PAIN Act HR 1227 · introduced 2025-02-12 · latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determ… | — | HR 1227 | lobbying_bill_mention |
co acted on bill with (3)
| date | dir | entity | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | ← | Tillis, Thomas | — | s475-119 | lda_filing |
| 2026-01-01 | ← | Tillis, Thomas | — | s475-119 | lda_filing |
| 2026-01-01 | ← | Tillis, Thomas | — | s475-119 | lda_filing |